# A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

> **NCT05650203** · PHASE1 · WITHDRAWN · sponsor: **Shanghai Junshi Bioscience Co., Ltd.**

## Conditions studied

- Primary Condition: Advanced Tumors

## Interventions

- **DRUG:** JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006

## Key facts

- **NCT ID:** NCT05650203
- **Lead sponsor:** Shanghai Junshi Bioscience Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-31
- **Primary completion:** 2025-10-25
- **Final completion:** 2026-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** the research and develop strategy of Product JS009 adjustment
- **Last updated:** 2023-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05650203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05650203, "A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05650203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*